NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/09/2025
Voltar para busca
Dado oficial do USPTO
A2 BIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
23/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
15/02/2023
Data de registro
23/09/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/09/2025
Última transação
23/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/05/2023
Primeiro uso no comércio
01/05/2023
Código do desenho
4
Tipo de titular
03
Localização do titular
Agoura Hills, CA
Examinador
KOLODNER, LOUIS
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
A2 Biotherapeutics, Inc.
Representantes
Joi A. White CARR & FERRELL LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Therapeutics in the nature of cellsproteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cellsproteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cellsproteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes
Classe 40
Custom manufacturing of therapeuticsbiotherapeuticsmedicinespharmaceuticals; manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cellscellular targetsproteinsantibodies for others for treatment and prevention of cancer
Classe 42
Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeuticsbiotherapeuticsmedicinespharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
23/09/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/09/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/09/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
26/08/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
25/08/2025
EX3G
SOU EXTENSION 3 GRANTED
25/08/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
25/08/2025
EEXT
SOU TEAS EXTENSION RECEIVED
12/08/2025
EXT3
SOU EXTENSION 3 FILED
11/08/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/08/2025
IUAF
USE AMENDMENT FILED
08/05/2025
DRRR
DIVISIONAL REQUEST RECEIVED
08/05/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
08/05/2025
EISU
TEAS STATEMENT OF USE RECEIVED
08/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/02/2025
EX2G
SOU EXTENSION 2 GRANTED
20/02/2025
EXT2
SOU EXTENSION 2 FILED
19/02/2025
EEXT
SOU TEAS EXTENSION RECEIVED
19/02/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19/08/2024
EX1G
SOU EXTENSION 1 GRANTED
19/08/2024
EXT1
SOU EXTENSION 1 FILED
19/08/2024
EEXT
SOU TEAS EXTENSION RECEIVED
19/08/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/12/2023
PUBO
PUBLISHED FOR OPPOSITION
26/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/11/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
17/11/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/11/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
17/11/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/11/2023
DOCK
ASSIGNED TO EXAMINER
14/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/03/2023
NWAP
NEW APPLICATION ENTERED
18/02/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace A2 BIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.